Lista de obras - Inmaculada Hernandez - Dominio Público Uruguay

A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.

artículo científico publicado en 2018

Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy-Reply

artículo científico publicado en 2018

Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation

artículo científico publicado en 2020

Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation

artículo científico publicado en 2016

Assessment of Price Changes of Existing Tumor Necrosis Factor Inhibitors After the Market Entry of Competitors

scientific article published on 01 May 2019

Association of Antidementia Therapies With Time to Skilled Nursing Facility Admission and Cardiovascular Events Among Elderly Adults With Alzheimer Disease

artículo científico publicado en 2019

Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence

article

Cardiac resynchronization therapy using pacemakers vs defibrillators in patients with nonischemic cardiomyopathy: The United States experience from 2007 to 2014

artículo científico publicado en 2019

Changes in Drug Pricing After Drug Shortages in the United States

scientific article published on 18 September 2018

Comparing Adoption of Breakthrough and "Me-too" Drugs among Medicare Beneficiaries: A Case Study of Dipeptidyl Peptidase-4 Inhibitors.

artículo científico publicado en 2017

Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data

artículo científico publicado en 2016

Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis.

artículo científico publicado en 2015

Comparing state, regional, and local variation in concurrent opioid and benzodiazepine use

artículo científico publicado en 2018

Comparing the Approval and Coverage Decisions of New Oncology Drugs in the United States and Other Selected Countries

artículo científico publicado en 2017

Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding

artículo científico publicado en 2018

Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.

artículo científico publicado en 2017

Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function

scientific article published on 15 October 2016

Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation

artículo científico publicado en 2018

Estimating Discounts for Top Spending Drugs in Medicare Part D

artículo científico publicado en 2020

Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries.

artículo científico publicado en 2016

Exposure-Response Association Between Concurrent Opioid and Benzodiazepine Use and Risk of Opioid-Related Overdose in Medicare Part D Beneficiaries

artículo científico publicado en 2018

Geographic Variation in the Use of Oral Anticoagulation Therapy in Stroke Prevention in Atrial Fibrillation

artículo científico publicado en 2017

Impact of community pharmacist-provided preventive services on clinical, utilization, and economic outcomes: An umbrella review

scientific article published on 23 August 2018

Incidence of fracture events with teriparatide: role of study design

artículo científico publicado en 2015

Interpreting COVID-19 Test Results: a Bayesian Approach

artículo científico publicado en 2020

Joint Latent Class Analysis of Oral Anticoagulation Use and Risk of Stroke or Systemic Thromboembolism in Patients with Atrial Fibrillation

artículo científico publicado en 2021

Lowering the P Value Threshold

artículo científico publicado en 2018

Number of manufacturers and generic drug pricing from 2005 to 2017

scientific article published on 01 July 2019

Outcomes of Patients With Atrial Fibrillation Newly Recommended for Oral Anticoagulation Under the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline.

artículo científico publicado en 2018

Pharmaceutical Use and Spending Trend in Medicare Beneficiaries With Dementia, From 2006 to 2012.

artículo científico publicado en 2017

Revisiting Outcomes-Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab

scientific article published on 01 September 2017

Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data

artículo científico publicado en 2015

Risk of bleeding with dabigatran in atrial fibrillation

artículo científico publicado en 2015

Savings from the EpiPen Authorized Generic: a Retrospective Analysis of Medicaid Data

scientific article published on 01 September 2019

Statins for Primary Prevention of Cardiovascular Disease

artículo científico publicado en 2019

The Contribution Of New Product Entry Versus Existing Product Inflation In The Rising Costs Of Drugs

artículo científico publicado en 2019

Time to reconsider dabigatran 110 mg in the USA.

artículo científico

Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy.

artículo científico publicado en 2018

Trajectories of Oral Anticoagulation Adherence Among Medicare Beneficiaries Newly Diagnosed With Atrial Fibrillation

scientific article published on 13 June 2019

Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018

artículo científico publicado en 2019

Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D

artículo científico publicado en 2019

Using predictive analytics and big data to optimize pharmaceutical outcomes.

artículo científico publicado en 2017

Lista de obras de Inmaculada Hernandez

A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.

Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy-Reply

Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation

Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation

Assessment of Price Changes of Existing Tumor Necrosis Factor Inhibitors After the Market Entry of Competitors

Association of Antidementia Therapies With Time to Skilled Nursing Facility Admission and Cardiovascular Events Among Elderly Adults With Alzheimer Disease

Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence

Cardiac resynchronization therapy using pacemakers vs defibrillators in patients with nonischemic cardiomyopathy: The United States experience from 2007 to 2014

Changes in Drug Pricing After Drug Shortages in the United States

Comparing Adoption of Breakthrough and "Me-too" Drugs among Medicare Beneficiaries: A Case Study of Dipeptidyl Peptidase-4 Inhibitors.

Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data

Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis.

Comparing state, regional, and local variation in concurrent opioid and benzodiazepine use

Comparing the Approval and Coverage Decisions of New Oncology Drugs in the United States and Other Selected Countries

Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding

Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.

Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function

Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation

Estimating Discounts for Top Spending Drugs in Medicare Part D

Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries.

Exposure-Response Association Between Concurrent Opioid and Benzodiazepine Use and Risk of Opioid-Related Overdose in Medicare Part D Beneficiaries

Geographic Variation in the Use of Oral Anticoagulation Therapy in Stroke Prevention in Atrial Fibrillation

Impact of community pharmacist-provided preventive services on clinical, utilization, and economic outcomes: An umbrella review

Incidence of fracture events with teriparatide: role of study design

Interpreting COVID-19 Test Results: a Bayesian Approach

Joint Latent Class Analysis of Oral Anticoagulation Use and Risk of Stroke or Systemic Thromboembolism in Patients with Atrial Fibrillation

Lowering the P Value Threshold

Number of manufacturers and generic drug pricing from 2005 to 2017

Outcomes of Patients With Atrial Fibrillation Newly Recommended for Oral Anticoagulation Under the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline.

Pharmaceutical Use and Spending Trend in Medicare Beneficiaries With Dementia, From 2006 to 2012.

Revisiting Outcomes-Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab

Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data

Risk of bleeding with dabigatran in atrial fibrillation

Savings from the EpiPen Authorized Generic: a Retrospective Analysis of Medicaid Data

Statins for Primary Prevention of Cardiovascular Disease

The Contribution Of New Product Entry Versus Existing Product Inflation In The Rising Costs Of Drugs

Time to reconsider dabigatran 110 mg in the USA.

Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy.

Trajectories of Oral Anticoagulation Adherence Among Medicare Beneficiaries Newly Diagnosed With Atrial Fibrillation

Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018

Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D

Using predictive analytics and big data to optimize pharmaceutical outcomes.